Key result
Renal denervation of the native kidneys in a kidney transplant recipient reduced 24-h ambulatory blood pressure from 143/89 to 134/84 mmHg at 6 months, allowing reduction of antihypertensive agents.
Why the study?
Does renal denervation of native kidneys reduce blood pressure in kidney transplant recipients with drug-resistant hypertension?
Case Report (n=1)
Does renal denervation of native kidneys reduce blood pressure in kidney transplant recipients with drug-resistant hypertension?
Renal denervation of native kidneys successfully reduced blood pressure and medication burden in a kidney transplant recipient with resistant hypertension without affecting graft function.
There is a strong rationale for renal denervation (RDN) of the native kidneys in kidney transplant recipients with treatment-resistant hypertension. We present a patient with a stable graft function, who underwent RDN for posttransplant therapy-resistant hypertension (24-h ambulatory blood pressure measurement (ABPM) 143/89 mmHg, while compliantly using five different antihypertensive agents). After RDN, BP measurements and orthostatic complaints required withdrawal of two antihypertensive agents and halving a third. At 6 months, ABPM was 134/84 mmHg and allograft function remained unchanged. This case calls for designing well-designed prospective studies on RDN in kidney transplant recipients.
No takes yet. Share an insight, caveat, or question.
Dobrowolski et al. (2014) conducted a case report in treatment-resistant hypertension after kidney transplantation (n=1). Renal denervation (RDN) of the native kidneys was evaluated on 24-h ambulatory blood pressure measurement (ABPM). Renal denervation of the native kidneys in a kidney transplant recipient reduced 24-h ambulatory blood pressure from 143/89 to 134/84 mmHg at 6 months, allowing reduction of antihypertensive agents.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: